LT2389352T - Arginazės inhibitoriai ir naudojimo būdai - Google Patents

Arginazės inhibitoriai ir naudojimo būdai

Info

Publication number
LT2389352T
LT2389352T LTEP10734002.8T LT10734002T LT2389352T LT 2389352 T LT2389352 T LT 2389352T LT 10734002 T LT10734002 T LT 10734002T LT 2389352 T LT2389352 T LT 2389352T
Authority
LT
Lithuania
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
LTEP10734002.8T
Other languages
English (en)
Inventor
David Christianson
Bruce Tomczuk
Richard POTTORF
Andrew Colasanti
Gary Olson
Original Assignee
The Trustees Of The University Of Pennsylvania
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, Astrazeneca Uk Limited filed Critical The Trustees Of The University Of Pennsylvania
Publication of LT2389352T publication Critical patent/LT2389352T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
LTEP10734002.8T 2009-01-26 2010-01-26 Arginazės inhibitoriai ir naudojimo būdai LT2389352T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14727009P 2009-01-26 2009-01-26
PCT/US2010/022090 WO2010085797A2 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
LT2389352T true LT2389352T (lt) 2019-06-10

Family

ID=42354317

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10734002.8T LT2389352T (lt) 2009-01-26 2010-01-26 Arginazės inhibitoriai ir naudojimo būdai

Country Status (16)

Country Link
US (4) US20100189644A1 (lt)
EP (1) EP2389352B1 (lt)
JP (2) JP2012515799A (lt)
CA (1) CA2749853C (lt)
CY (1) CY1121815T1 (lt)
DK (1) DK2389352T3 (lt)
ES (1) ES2729474T3 (lt)
HR (1) HRP20191433T1 (lt)
HU (1) HUE046932T2 (lt)
LT (1) LT2389352T (lt)
PL (1) PL2389352T3 (lt)
PT (1) PT2389352T (lt)
RS (1) RS58965B1 (lt)
SI (1) SI2389352T1 (lt)
TR (1) TR201910726T4 (lt)
WO (1) WO2010085797A2 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
DK2632927T3 (en) * 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
CN103402549A (zh) * 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
WO2013059437A1 (en) * 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US10299377B2 (en) 2011-12-22 2019-05-21 Fujifilm Corporation Conductive sheet and touch panel
JP6152167B2 (ja) 2012-04-18 2017-06-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としての環拘束性類似体
WO2014088326A1 (ko) * 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CA2990192A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CA3000996A1 (en) * 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
TWI710565B (zh) * 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
JP6581308B2 (ja) * 2016-10-17 2019-09-25 一般社団法人 金沢大整形 癌治療剤
CN110352063A (zh) 2016-11-08 2019-10-18 卡里塞拉生物科学股份公司 精氨酸酶抑制剂组合疗法
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EA201992695A1 (ru) 2017-05-12 2020-05-15 Калитера Байосайнсиз, Инк. Способ получения (3r,4s)-3-ацетамидо-4-аллил-n-(трет-бутил)пирролидин-3-карбоксамида
EP3774843B1 (en) 2018-03-29 2022-05-25 Molecure SA Dipeptide piperidine derivatives
RU2695333C1 (ru) * 2018-09-24 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек ингибитором аргиназы II в эксперименте
RU2696580C1 (ru) * 2018-09-25 2019-08-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте
KR20210126044A (ko) * 2019-02-08 2021-10-19 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477391A (en) * 1981-08-14 1984-10-16 Collins James F Amino acid isomers, their production and their medicinal use
CA2305703A1 (en) * 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
EP1351674A4 (en) * 2000-04-12 2004-12-22 Cornell Res Foundation Inc PHARMACOTHERAPY FOR VASCULAR DYSFUNCTION ASSOCIATED WITH THE DEFICIENT BIOACTIVITY OF NITRIC OXIDE
WO2005025620A2 (en) * 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
US20100056480A1 (en) * 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis

Also Published As

Publication number Publication date
HUE046932T2 (hu) 2020-04-28
JP2015205891A (ja) 2015-11-19
EP2389352A4 (en) 2013-02-20
HRP20191433T1 (hr) 2019-11-15
PL2389352T3 (pl) 2019-10-31
EP2389352B1 (en) 2019-05-08
US20100189644A1 (en) 2010-07-29
CY1121815T1 (el) 2020-07-31
PT2389352T (pt) 2019-08-23
US10118936B2 (en) 2018-11-06
AU2010206535A1 (en) 2011-07-28
CA2749853C (en) 2018-08-21
RS58965B1 (sr) 2019-08-30
JP6177832B2 (ja) 2017-08-09
TR201910726T4 (tr) 2019-08-21
SI2389352T1 (sl) 2019-08-30
US20200223871A1 (en) 2020-07-16
EP2389352A2 (en) 2011-11-30
WO2010085797A2 (en) 2010-07-29
ES2729474T3 (es) 2019-11-04
DK2389352T3 (da) 2019-07-29
CA2749853A1 (en) 2010-07-29
WO2010085797A3 (en) 2010-11-04
US20160194340A1 (en) 2016-07-07
US20190127395A1 (en) 2019-05-02
JP2012515799A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
HUE046932T2 (hu) Argináz inhibitorok és felhasználási eljárások
HK1213769A1 (zh) 精氨酸酶抑制劑及其使用方法
IL240771A0 (en) Benzoxazole kinase inhibitors and methods of use
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2379561A4 (en) MLK INHIBITORS AND METHODS OF USE
HK1160119A1 (en) Kinase inhibitors and methods of use
IL224389A (en) Demetylase inhibitors of arsylcyclopropylamine-based lsd1 and their medical use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
HK1149933A1 (en) Diazacarbazoles and methods of use
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL209548A0 (en) Diazacarbazoles and methods of use
EP2344204A4 (en) TELOMERASE INHIBITOR AND METHOD OF USE THEREOF
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
EP2393787A4 (en) CADHERINE 11 INHIBITORS AND METHOD FOR THEIR USE
ZA201301795B (en) Inhibitors of notum pectinacetylesterase and methods of their use
EP2242367A4 (en) REL INHIBITORS AND METHODS OF USE
ZA201106083B (en) Inhibitors of viral integrase and methods of use
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法